SEC’s MyNyloxin lawsuit survives motion to dismiss
The SEC’s lawsuit against Nutra Pharma Corporation and CEO Erik Deitsch, has survived a Motion to Dismiss. Some of the defenses raised in the motion however were upheld. As part of their lawsuit, the SEC alleged Deitsch published press-releases with bogus info. The press-releases were published pursuant to consultancy agreements with Wall Street Buy, New […]
SEC’s MyNyloxin lawsuit survives motion to dismiss Read More »